Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults

Completed · Phase 1

Conditions studied: Obesity

In brief

The purpose of this trial is to evaluate the safety and tolerability of single escalating doses of Peptide YY3-36 and to determine effects on food intake and serum hormones when administered by intravenous infusion to otherwise healthy overweight adult subjects.

Key facts

Study ID

NCT00331175

Run by

Pfizer

People needed

31

Starts

2006-07-01

Expected to finish

2006-12-01

Last updated by the study team

2006-12-15

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• BMI 27-35 kg/m2

You may not qualify if…

• Women of childbearing potential

Where it is running

• Pfizer Investigational Site — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.